2019
Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome
Devin JK, Nian H, Celedonio JE, Wright P, Brown NJ. Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome. The Journal Of Clinical Endocrinology & Metabolism 2019, 105: dgz028. PMID: 31529097, PMCID: PMC7947776, DOI: 10.1210/clinem/dgz028.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersBlood GlucoseCross-Over StudiesDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDouble-Blind MethodFemaleFollow-Up StudiesGlucose Tolerance TestHuman Growth HormoneHumansIntra-Abdominal FatMiddle AgedPolycystic Ovary SyndromePrognosisSitagliptin PhosphateYoung AdultConceptsOral glucose tolerance testPolycystic ovarian syndromeVisceral adiposityVascular functionGrowth hormoneOvarian syndromeGH secretionGlucagon-like peptide-1Increased visceral adiposityMaximal glucose responseOvernight GH secretionOvernight growth hormoneEarly insulin secretionGlucose tolerance testVenous samplingCrossover studyVisceral fatCrossover treatmentTolerance testBlood glucoseDPP4 inhibitionInsulin secretionPeak glucoseGlucose levelsPeptide-1
2018
DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition
Hubers SA, Wilson JR, Yu C, Nian H, Grouzmann E, Eugster P, Shibao CA, Billings FT, Jafarian Kerman S, Brown NJ. DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition. Hypertension 2018, 72: 712-719. PMID: 29987109, PMCID: PMC6202157, DOI: 10.1161/hypertensionaha.118.11498.Peer-Reviewed Original ResearchConceptsNPY infusionPlacebo-controlled crossover studyAngiotensin-converting enzyme inhibitorAldosterone system inhibitionDose-dependent vasoconstrictionIntra-arterial enalaprilatAngiotensin receptor blockersForearm blood flowHigh-risk patientsOrder of treatmentReceptor blockersVasoconstrictor effectVasoconstrictor responsesCardiovascular effectsRenin-AngiotensinBrachial arteryHeart failureNorepinephrine releaseCrossover studyEndogenous NPYY1 receptorCrossover treatmentSystem inhibitionY2 receptorsDPP4 inhibitionDipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women
Wilson JR, Brown NJ, Nian H, Yu C, Bidlingmaier M, Devin JK. Dipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women. Journal Of The American Heart Association 2018, 7: e008000. PMID: 29478970, PMCID: PMC5866333, DOI: 10.1161/jaha.117.008000.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultCross-Over StudiesDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDouble-Blind MethodFemaleFibrinolysisHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleSecretory PathwaySex FactorsSitagliptin PhosphateTime FactorsTissue Plasminogen ActivatorUp-RegulationVasodilationYoung AdultConceptsFree insulin-like growth factor-1Insulin-like growth factor-1Growth factor-1GH secretionGrowth hormoneGHR blockadeVascular resistanceFactor 1Nitric oxideTissue plasminogen activator activityPeptidase-4 inhibitionImpaired endothelial functionGrowth hormone secretionReceptor-dependent effectsDipeptidyl peptidase-4Study drugEndothelial functionPlasminogen activator activityCrossover studyHormone secretionPeptidase-4VasodilationHealthy adultsGH receptorInhibition potentiates
2016
Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study
Kodaman N, Aldrich MC, Sobota R, Asselbergs FW, Poku KA, Brown NJ, Moore JH, Williams SM. Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study. PLOS ONE 2016, 11: e0162753. PMID: 27732601, PMCID: PMC5061429, DOI: 10.1371/journal.pone.0162753.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood GlucoseBlood PressureBody Mass IndexCardiovascular DiseasesCholesterolCholesterol, HDLCholesterol, LDLCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleGhanaHumansHypertensionMaleMiddle AgedObesityPlasminogen Activator Inhibitor 1PrevalenceRisk FactorsSmokingSurveys and QuestionnairesTissue Plasminogen ActivatorTriglyceridesUrbanizationYoung AdultConceptsCardiovascular disease risk factorsDisease risk factorsRisk factorsUrban residenceWorse cardiovascular risk profileCardiovascular risk profileRelated clinical outcomesPopulation-based surveyCross-sectional studyFibrinolytic markersTotal cholesterolCholesterol profileClinical outcomesLDL cholesterolCardiovascular diseaseBMI adjustmentHigh riskRural participantsRisk profileLarger studyT-PAUrban womenUrban menObesityCholesterolPlasminogen Activator Inhibitor‐1 and Diagnosis of the Metabolic Syndrome in a West African Population
Kodaman N, Aldrich MC, Sobota R, Asselbergs FW, Brown NJ, Moore JH, Williams SM. Plasminogen Activator Inhibitor‐1 and Diagnosis of the Metabolic Syndrome in a West African Population. Journal Of The American Heart Association 2016, 5: e003867. PMID: 27697752, PMCID: PMC5121488, DOI: 10.1161/jaha.116.003867.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntihypertensive AgentsBlood GlucoseBlood PressureBody Mass IndexCholesterol, HDLCross-Sectional StudiesDiabetes MellitusFastingFemaleGhanaHumansHypertensionHypoglycemic AgentsMaleMetabolic SyndromeMiddle AgedPlasminogen Activator Inhibitor 1PrevalenceRural PopulationTriglyceridesUrban PopulationYoung AdultConceptsPlasminogen activator inhibitor-1Activator inhibitor-1Metabolic syndromeRisk factorsDiagnostic criteriaLow high-density lipoproteinInhibitor-1Relevance of MetSAge-standardized prevalenceConventional risk factorsCardiovascular disease riskBody mass indexMetS diagnostic criteriaPAI-1 levelsHigh-density lipoproteinCross-sectional analysisMetS prevalenceIschemic eventsMetS componentsMetS criteriaWest African populationsMass indexPlasma levelsGhanaian menAntifibrinolytic factors
2014
Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans
Ramirez CE, Shuey MM, Milne GL, Gilbert K, Hui N, Yu C, Luther JM, Brown NJ. Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. Prostaglandins And Other Lipid Mediators 2014, 113: 38-44. PMID: 25173047, PMCID: PMC4253976, DOI: 10.1016/j.prostaglandins.2014.08.001.Peer-Reviewed Original ResearchConceptsInsulin sensitivity indexEpoxyeicosatrienoic acidsInsulin sensitivityHigher insulin sensitivity indexPlasma epoxyeicosatrienoic acidsGlucose-stimulated insulin secretionBody mass indexArg/ArgSoluble epoxide hydrolase activitySoluble epoxide hydrolaseMetabolic syndromeMass indexDisposition indexInsulin resistanceHyperglycemic clampInsulin secretionSensitivity indexEpoxide hydrolase activityEPHX2Hydrolase activitySecretionPhenotyping studiesMetabolic phenotyping studiesEpoxide hydrolaseGenetic variantsGenetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans
Laffer CL, Elijovich F, Eckert GJ, Tu W, Pratt JH, Brown NJ. Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans. International Journal Of Cardiology Cardiovascular Risk And Prevention 2014, 8: 475-480. PMID: 25064769, PMCID: PMC4115247, DOI: 10.1016/j.jash.2014.04.011.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBlack or African AmericanBlood PressureCytochrome P-450 CYP4ACytochrome P-450 Enzyme SystemDNADouble-Blind MethodFemaleGenetic VariationGenotypeHumansHypertensionMaleMiddle AgedMineralocorticoid Receptor AntagonistsPilot ProjectsRadioimmunoassayUnited StatesYoung AdultConceptsBlood pressure responseBlood pressureReceptor antagonismPressure responseMineralocorticoid receptor antagonismSalt-sensitive hypertensionAfrican AmericansExploratory pilot studyGC individualsAldosterone responseResistant hypertensionAntihypertensive effectTreatment responsePrecluded analysisCC genotypeCC homozygotesSpironolactoneC alleleHypertensionPilot studyENaC activationCYP4A11AmilorideActivation of ENaC.ENaC inhibition
2010
Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) Is Associated With Forearm Vasodilator Responses in Humans
Lee CR, Pretorius M, Schuck RN, Burch LH, Bartlett J, Williams SM, Zeldin DC, Brown NJ. Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) Is Associated With Forearm Vasodilator Responses in Humans. Hypertension 2010, 57: 116-122. PMID: 21098312, PMCID: PMC3020911, DOI: 10.1161/hypertensionaha.110.161695.Peer-Reviewed Original ResearchConceptsForearm blood flowVariant allele carriersForearm vasodilator responseForearm vascular resistanceSoluble epoxide hydrolaseVascular resistanceVasodilator responseBlood flowAllele carriersSodium nitroprussideVascular functionStrain-gauge venous occlusion plethysmographyHighest forearm blood flowLower forearm vascular resistanceSignificant associationCytochrome P450-derived epoxyeicosatrienoic acidsEpoxide hydrolaseVenous occlusion plethysmographyCardiovascular disease riskEndothelium-independent mannerWild-type individualsOcclusion plethysmographyPotent vasodilatorEpoxyeicosatrienoic acidsPreclinical modelsLow-salt diet increases insulin resistance in healthy subjects
Garg R, Williams GH, Hurwitz S, Brown NJ, Hopkins PN, Adler GK. Low-salt diet increases insulin resistance in healthy subjects. Metabolism 2010, 60: 965-968. PMID: 21036373, PMCID: PMC3036792, DOI: 10.1016/j.metabol.2010.09.005.Peer-Reviewed Original ResearchConceptsLow-salt dietHomeostasis model assessment indexModel assessment indexBody mass indexInsulin resistanceLS dietUrine aldosteroneMass indexHS dietHealthy subjectsHigher homeostasis model assessment indexUrine norepinephrine excretionPlasma renin activityHigh-salt dietSympathetic nervous systemSerum angiotensin IIPathogenesis of diabetesUrine epinephrineNorepinephrine excretionRenin activitySerum aldosteroneBlood pressureSerum sodiumAngiotensin IIHealthy men
2009
Variation in the 4q25 Chromosomal Locus Predicts Atrial Fibrillation After Coronary Artery Bypass Graft Surgery
Body SC, Collard CD, Shernan SK, Fox AA, Liu KY, Ritchie MD, Perry T, Muehlschlegel JD, Aranki S, Donahue BS, Pretorius M, Estrada JC, Ellinor PT, Newton-Cheh C, Seidman CE, Seidman JG, Herman; D, Lichtner P, Meitinger T, Pfeufer A, Kääb S, Brown NJ, Roden DM, Darbar D. Variation in the 4q25 Chromosomal Locus Predicts Atrial Fibrillation After Coronary Artery Bypass Graft Surgery. Circulation Genomic And Precision Medicine 2009, 2: 499-506. PMID: 20031626, PMCID: PMC2801871, DOI: 10.1161/circgenetics.109.849075.Peer-Reviewed Original ResearchConceptsCoronary artery bypass graft surgeryArtery bypass graft surgeryPostoperative atrial fibrillationBypass graft surgeryGraft surgeryAtrial fibrillationSingle nucleotide polymorphismsValidation cohortDiscovery cohortCardiac surgery cohortConcurrent valve surgeryCommon adverse eventsCohort of patientsAdditive odds ratioMultiple comparisonsChromosome 4q25 variantsSurgery cohortValve surgeryAdverse eventsClinical predictorsAmbulatory populationOdds ratioClinical covariatesUS CentersMultivariate predictors